FDA Feels Heat Alongside J&J As House Oversight Investigates OTC Recall
This article was originally published in The Tan Sheet
FDA finds itself under congressional scrutiny alongside Johnson & Johnson even as the agency investigates and weighs possible enforcement against J&J following the firm's third OTC recall in eight months
You may also be interested in...
FDA will monitor more closely OTC manufacturing operations and require comprehensive changes at firms with systemic quality deficiencies as a result of its investigation of Johnson & Johnson's McNeil Consumer Healthcare
McNeil Consumer Healthcare adds executive posts for quality assurance in its response to FDA's warning about a problem with packaging materials that led to a massive recall of OTC products
Drug companies likely will face less combative investigations into their activities by the House Oversight and Government Reform Committee during the 111th Congress